Protein A colorimetric resins are the most extensively used affinity purifiers in bio-manufacturing and other industries. Protein A colorimetry is a robust, high-throughput chromatography method and is used primarily as a capture step because of its inherent precision.
Approval and launch of new biosimilars is expected to propel growth of the protein A resin market. For instance, in December 2020, Sandoz Canada Inc., a generics and biosimilars manufacturer and a division of the Switzerland-based multinational Novartis AG, received Health Canada authorization for Hyrimoz (adalimumab injection, reference biologic drug: Humira) on November 4, 2020 for marketing in Canada. Hyrimoz, the new biosimilar, has been approved for the treatment of rheumatoid arthritis, polyarticular juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, adult Crohn’s disease, ulcerative colitis, hidradenitis suppurativa, psoriasis and adult uveitis.
Moreover, high prevalence of chronic diseases is also expected to aid in growth of the protein A resin market. For instance, according to the American Cancer Society, in 2019, there will be an estimated 1,762,450 new cancer cases diagnosed and 606,880 cancer deaths in the U.S.
Increasing adoption of chromatography resins is expected to propel growth of the protein A resin market. For instance, in March 2020, Purolite Ltd. announced to supply its Praesto Jetted A50, an agarose-based Protein A chromatography resin, for use as part of the commercial manufacturing process of an FDA-approved monoclonal antibody treatment by a contract manufacturing organization. Similarly, in November 2020, Purolite Ltd. announced to supply its Protein A capture resin, Praesto Jetted A50 to WuXi Biologics, a global company with leading open-access biologics technology, for immediate use. WuXi Biologics.
Emergence of Covid-19 is expected to offer lucrative growth opportunities for players in the protein A resin market. For instance, in October 2020, Repligen Corporation and Navigo Proteins GmbH, a premier protein engineering company, announced their successful development of an affinity ligand targeting the spike protein, to be utilized in the purification of COVID-19 vaccines.
Major players operating in the global protein A resin market include, GE Healthcare, Thermo Fisher Scientific, Repligen, Avantor, Inc., Purolite Ltd., Tosoh Bioscience, EMD Millipore, Novasep, GenScript Biotech Corporation, Purolite Life Sciences, and Expedeon Ltd.
Major players operating in the global protein A resin market are focused on approval and launch of new products to expand their product portfolio. For instance, in March 2020, Avantor, Inc. launched a new recombinant Protein A affinity chromatography resin used to purify antibodies during mAbs production.